Check out our NMA on comparative efficacy of advanced therapies for achieving endoscopic outcomes in CD Vipul Jairath MBChB DPhil Neeraj Narula Laurent Peyrin-Biroulet Talat Bessissow CGH cghjournal.org/article/S1542-…

⚫️⚫️ The Canadian Digestive Diseases Week #cddw2024 will be held from February 27 to March 3, 2024, in Toronto, Ontario. Abstracts are now available in the special volume of the Journal of the Canadian Assn of Gastroenterology CAG

TRIUMPH study evaluating the efficacy of tofacitinib in ASUC. Congratulations to Neeraj Narula for presenting the data on behalf of the The Canadian IBD Research Consortium (CIRC) investigators #ECCO2024 Dr Brian Bressler John K. Marshall MD Pfizer Canada

1/3 Our top 3 abstracts for #ECCO24 for ibdupdate.ca Jeffrey McCurdy MD PhD Neeraj Narula Reena Khanna Cynthia Seow #talatbessissow #MondayNightIBD CAG IBDHorizons #1 VIVID 1 Miri is effective in CD. Miri not superior to Ust. Are all IL-23's the same? Vipul Jairath MBChB DPhil

2/3 HELIOS trial. HD-WLE with segmental re-inspection (increased inspection time ) was non inferior to HD-CE for colorectal neoplasia detection in IBD patients. Is this the end of chromoendoscopy? Jean-Frederic Colombel

3/3 TRIUMPH study: tofacitinib 10 mg twice a day was effective in steroid refractory ASUC (including in biologic failures): 57% 7 day clinical response. A good 2nd line option in ASUC. Will this ever replace IFX as a possible first line treatment of ASUC? Neeraj Narula

Nice work د. محمد عبدالله شهاب

Hit the target? Our latest paper in CGH finds achieving MM-SES-CD <22.5 and SES-CD <4 in Crohn's disease is associated with low risk of disease progression and is a suitable target in clinical trials and practice for endoscopic healing. doi.org/10.1016/j.cgh.…

Important study for clinical practice and endoscopic target!

Interested in pursuing and IBD fellowship at McGill? The application process opens next week for the 2025-2026 year! mcgillibd.ca/fellowship-tra…

Honored to have Matthieu Allez speaking about personalized/precision medicine in IBD at our McGill GI Research Day! McGill_DOM

Congratulations Neeraj Narula The Canadian IBD Research Consortium (CIRC) for an important paper

Glad to be a part of another successful The Canadian IBD Research Consortium (CIRC) study. Ustekinumab persistence in bio-naive Crohn's disease remarkably high in the real-world, approaching 94% persistence at one-year! Congrats Talat Bessissow Christopher Ma MD MPH Vipul Jairath MBChB DPhil sciencedirect.com/science/articl…

Important reassuring data for patients that must remain on Upa

Our review paper 👇 Up to date management of fistulizing Crohn's disease tandfonline.com/doi/full/10.10… Talat Bessissow Beatriz Gros #MondayNightIBD

More data not supportive if TDM for vedo. Journal of the Canadian Assn of Gastroenterology

How would you rank novel therapies such as etrasimod, risankizumab, mirikizumab, and guselkumab in UC ❓ What treatment 🎯 you are interested in ❓ Our recent NMA at CGH cghjournal.org/article/S1542-… Talat Bessissow Vipul Jairath MBChB DPhil Beatriz Gros #MondayNightIBD Shrinivas Bishu